disease remission;time to clinical improvement;overall rates of clinical improvement assessed at days 7; 14; and 28;time to chest CT improvement; time to virus nucleic acid negative-conversion;overall rates of radiological improvement on days 7; 14; and 28;overall rates of virus nucleic acid negative-conversion on qRT-PCR in nasopharyngeal swabs samples on days 7; 14; and 28;serious adverse events;

disease remission;time to clinical improvement;overall rates of clinical improvement assessed at days 7; 14; and 28;time to chest CT improvement; time to virus nucleic acid negative-conversion;overall rates of radiological improvement on days 7; 14; and 28;overall rates of virus nucleic acid negative-conversion on qRT-PCR in nasopharyngeal swabs samples on days 7; 14; and 28;serious adverse events;

????;time to clinical improvement;overall rates of clinical improvement assessed at days 7; 14; and 28;time to chest CT improvement; time to virus nucleic acid negative-conversion;overall rates of radiological improvement on days 7; 14; and 28;overall rates of virus nucleic acid negative-conversion on qRT-PCR in nasopharyngeal swabs samples on days 7; 14; and 28;serious adverse events;

????;time to clinical improvement;overall rates of clinical improvement assessed at days 7; 14; and 28;time to chest CT improvement; time to virus nucleic acid negative-conversion;overall rates of radiological improvement on days 7; 14; and 28;overall rates of virus nucleic acid negative-conversion on qRT-PCR in nasopharyngeal swabs samples on days 7; 14; and 28;serious adverse events;